


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Linaclotide. [Updated 2019 Feb 7]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Linaclotide

Revised: February 7, 2019.

CASRN: 851199-59-2



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of linaclotide during breastfeeding. Linaclotide is minimally absorbed from the gastrointestinal tract and the drug and its active metabolite is not measurable in plasma following administration of recommended doses. Linaclotide would not be expected to enter the breastmilk and cause any adverse effects in breastfed infants

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Irritable Bowel Syndrome) Lubiprostone, Plecanatide, Polyethylene Glycol, Psyllium

Substance Identification

Substance Name

Linaclotide

CAS Registry Number

851199-59-2

Drug Class

Breast Feeding Lactation Gastrointestinal Agents Peptides Guanylate Cyclase C Agonists

Laxatives